Clinical Trials
34 trialsHER2 CR
Nagoya City University
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Pfizer
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Fudan University
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
Samsung Bioepis Co., Ltd.
AryoTrust® (Trastuzumab) Safety Study
AryoGen Pharmed Co.
BiOnHER
Institut Català d'Oncologia
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
Rawalpindi Medical College
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Zhejiang Cancer Hospital
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
NSABP Biospecimen Discovery Project
NSABP Foundation Inc
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
OmicsWay Corp.
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Peking University Third Hospital
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Peking University Third Hospital
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Shandong Cancer Hospital and Institute
HerSCin
Hoffmann-La Roche
MotHER
Genentech, Inc.
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
PACE in BC
Vanderbilt University Medical Center
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
Hoffmann-La Roche
Prognostic and Predictive Factors for Small Breast Tumors
Karolinska Institutet
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
University of California, San Francisco
HERODOT
Hoffmann-La Roche
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
Hoffmann-La Roche
microRNA of Human Epidermal Growth Factor Receptor 2 (HER2)Positive Patient Treated With Herceptin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
National Guard Health Affairs
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Hoffmann-La Roche
CADY Study ICORG 08-01
Cancer Trials Ireland
Brain Metastasis in Breast Cancer Patients
GlaxoSmithKline
Chemotherapeutic Agents in Brain/Breast
Case Comprehensive Cancer Center
Real World Efficiency of Trastuzumab in Early Breast Cancer
Maastricht University Medical Center